US Neurologist Advocates Rapid Emergency Diagnosis to Prevent Blindness from Giant Cell Arteritis
Dr Jay Avasarala’s study finds emergency departments consistently miss GCA testing and proposes ultrasound and AI tools as solutions
For patients over fifty presenting with sudden vision changes, a potentially blinding condition called Giant Cell Arteritis (GCA) is frequently overlooked in emergency departments worldwide, according to a new study led by Dr Jagannadha “Jay” Avasarala.
The paper reveals that more than sixty percent of such patients receive no test for GCA, and in some categories that figure rises as high as ninety-four percent.
GCA is a form of large-vessel inflammation that can swiftly block blood flow to the eye and lead to permanent blindness if not treated.
It also carries risks of stroke and aortic aneurysm.
Dr Avasarala, professor of neurology at the University of Kentucky College of Medicine and director of the Comprehensive Care Centre for MS and Neuroimmunology at the Kentucky Neuroscience Institute, emphasises that “every minute counts” when vision is at risk.
His team’s analysis of data from the University of Kentucky Medical Centre and a national health-data platform covering nearly three hundred million patients identified a critical gap: when GCA is not considered promptly, not only are patients tested too late, but many are already treated with steroids—which can render diagnostic tests falsely negative.
The researchers found that in more than six in ten cases of acute ocular symptoms, no GCA test was performed; in certain subgroups this reached almost nine in ten.
To address this, Dr Avasarala highlights the value of the Temporal Artery Ultrasound (TAUS), a non-invasive scan that detects arterial inflammation in real time and outperforms the traditional temporal-artery biopsy, which is invasive and too slow for immediate treatment.
“Ultrasound offers real-time information,” he notes.
He argues that embedding TAUS into emergency-department protocols could dramatically improve outcomes—and prevent sight loss in patients who might otherwise present too late.
Looking ahead, Dr Avasarala and his collaborators have proposed a global model linking point-of-care ultrasound devices with artificial-intelligence-powered analysis and cloud-based data systems to enable instantaneous diagnosis—even in rural or under-resourced settings.
He frames GCA as a “stroke of the eye” and suggests that hospitals adopt fast-track pathways comparable with those for acute cerebrovascular events: immediate imaging, diagnosis and steroid administration.
Dr Avasarala’s research urges health-systems worldwide to wake up to a narrowly recognised but high-stakes condition, and to treat it with the urgency that intact vision demands.
The paper reveals that more than sixty percent of such patients receive no test for GCA, and in some categories that figure rises as high as ninety-four percent.
GCA is a form of large-vessel inflammation that can swiftly block blood flow to the eye and lead to permanent blindness if not treated.
It also carries risks of stroke and aortic aneurysm.
Dr Avasarala, professor of neurology at the University of Kentucky College of Medicine and director of the Comprehensive Care Centre for MS and Neuroimmunology at the Kentucky Neuroscience Institute, emphasises that “every minute counts” when vision is at risk.
His team’s analysis of data from the University of Kentucky Medical Centre and a national health-data platform covering nearly three hundred million patients identified a critical gap: when GCA is not considered promptly, not only are patients tested too late, but many are already treated with steroids—which can render diagnostic tests falsely negative.
The researchers found that in more than six in ten cases of acute ocular symptoms, no GCA test was performed; in certain subgroups this reached almost nine in ten.
To address this, Dr Avasarala highlights the value of the Temporal Artery Ultrasound (TAUS), a non-invasive scan that detects arterial inflammation in real time and outperforms the traditional temporal-artery biopsy, which is invasive and too slow for immediate treatment.
“Ultrasound offers real-time information,” he notes.
He argues that embedding TAUS into emergency-department protocols could dramatically improve outcomes—and prevent sight loss in patients who might otherwise present too late.
Looking ahead, Dr Avasarala and his collaborators have proposed a global model linking point-of-care ultrasound devices with artificial-intelligence-powered analysis and cloud-based data systems to enable instantaneous diagnosis—even in rural or under-resourced settings.
He frames GCA as a “stroke of the eye” and suggests that hospitals adopt fast-track pathways comparable with those for acute cerebrovascular events: immediate imaging, diagnosis and steroid administration.
Dr Avasarala’s research urges health-systems worldwide to wake up to a narrowly recognised but high-stakes condition, and to treat it with the urgency that intact vision demands.
